Citius Pharmaceuticals, Inc. (CTXR) Balance Sheet

The consistent decline in equity, coupled with a widening deficit in retained earnings, suggests that the company is struggling to maintain a stable capital foundation while awaiting regulatory milestones. Investors should monitor whether this trajectory forces further dilutive capital raises that could permanently impair the current equity structure.

The rapid depletion of cash reserves to $4.6M suggests that the company is operating under extreme liquidity duress. This lack of a sufficient buffer against operational shocks implies that the firm may be forced into unfavorable financing terms or asset divestitures to maintain its clinical trial momentum.

The persistent negative trend in retained earnings highlights the fundamental challenge of the company's business model, which relies entirely on external capital to survive. This ongoing erosion of equity suggests that shareholders are bearing the full brunt of the company's developmental risks without the benefit of a self-funding operational engine.